MNPR
NASDAQMonopar Therapeutics Inc.
News · 26 weeks52-25%
2026-04-192026-10-11
Mix2890d
- SEC Filings12(43%)
- Insider10(36%)
- Leadership3(11%)
- Other2(7%)
- Analyst1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Monopar Therapeutics Inc.4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Operating Officer Cittadine Andrew converted options into 4,384 shares and covered exercise/tax liability with 1,944 shares, increasing direct ownership by 4% to 58,054 units (SEC Form 4) to satisfy withholding tax4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Executive Officer Robinson Chandler converted options into 9,801 shares and covered exercise/tax liability with 4,344 shares, increasing direct ownership by 5% to 104,724 units (SEC Form 4) to satisfy withholding obligation4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Financial Officer Vu Quan Anh converted options into 614 shares and covered exercise/tax liability with 180 shares, increasing direct ownership by 20% to 2,655 units (SEC Form 4) (withholding obligation)4 - Monopar Therapeutics (0001645469) (Issuer)
- SECSEC Form 144 filed by Monopar Therapeutics Inc.144 - Monopar Therapeutics (0001645469) (Subject)
- INSIDERChief Executive Officer Robinson Chandler exercised 29,056 shares at a strike of $21.74 and sold $2,556,851 worth of shares (29,056 units at $88.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERAmendment: Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan and exercised 4,090 shares at a strike of $22.04 (SEC Form 4)4/A - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERAmendment: Director Anderson Raymond exercised 3,142 shares at a strike of $30.00 and sold $351,835 worth of shares (3,142 units at $111.98) as part of a pre-agreed trading plan (SEC Form 4)4/A - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERActing Chief Medical Officer Rioux Patrice exercised 1,380 shares at a strike of $0.01 and sold $111 worth of shares (1 units at $111.26) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 5,065 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERDirector Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan, decreasing direct ownership by 36% to 7,396 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERDirector Anderson Raymond sold $351,189 worth of shares (3,142 units at $111.77) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 23,751 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- SECSEC Form 144 filed by Monopar Therapeutics Inc.144 - Monopar Therapeutics (0001645469) (Subject)
- SECSEC Form 144 filed by Monopar Therapeutics Inc.144 - Monopar Therapeutics (0001645469) (Subject)
- SECSEC Form 144 filed by Monopar Therapeutics Inc.144 - Monopar Therapeutics (0001645469) (Subject)
- PRMonopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for the treatment of Wilson disease, have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking place November 5-9, 202
- ANALYSTMonopar Therapeutics downgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald downgraded Monopar Therapeutics from Overweight to Neutral and set a new price target of $119.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form 10-Q filed by Monopar Therapeutics Inc.10-Q - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesWILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates. Recent Program Developments ALXN1840 for Wilson Disease – Rolling NDA Submission Initiated On July 22, 2026, Monopar announced it had initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALXN1840. The FDA authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to
- SECSEC Form S-8 POS filed by Monopar Therapeutics Inc.S-8 POS - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form S-8 POS filed by Monopar Therapeutics Inc.S-8 POS - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form S-8 POS filed by Monopar Therapeutics Inc.S-8 POS - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form S-8 filed by Monopar Therapeutics Inc.S-8 - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form S-8 POS filed by Monopar Therapeutics Inc.S-8 POS - Monopar Therapeutics (0001645469) (Filer)
MNPR FAQ
7 questionsWhat does Monopar Therapeutics Inc. do?
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a...Where does MNPR stock trade?
Monopar Therapeutics Inc. (MNPR) is listed on NASDAQ.What sector and industry is MNPR in?
Monopar Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Monopar Therapeutics Inc. go public?
Monopar Therapeutics Inc. (MNPR) completed its IPO in 2019.What are analysts saying about MNPR?
Monopar Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Neutral on 2026-08-13.What companies are similar to MNPR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MNPR side-by-side with any of them on Quantisnow.How can I track MNPR on Quantisnow?
Quantisnow aggregates Monopar Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNPR to receive live email and push alerts on every new disclosure.